Management of intermittent allergic rhinitis (IAR) is suboptimal in the UK. An Australian community pharmacy-based intervention has been shown to help patients better self-manage their IAR. We conducted a pilot cluster-RCT in twelve Scottish community pharmacies to assess transferability of the Australian intervention. Trained staff in intervention pharmacies delivered the intervention to eligible customers (n=60). Non-intervention pharmacy participants (n=65) received usual care. Outcome measures included effect size of change in the mini-Rhinoconjunctivitis Quality of Life Questionnaire (miniRQLQ) between baseline, 1-week and 6-week follow-up. Trial procedures were well received by pharmacy staff, and customer satisfaction with the intervention was high. The standardised effect size for miniRQLQ total score was -0.46 (95% CI, -1.05, 0.13) for all participants and -0.14 (95% CI,-0.86, 0.57) in the complete case analysis, suggesting a small overall treatment effect in the intervention group. A full scale RCT is warranted to fully evaluate the effectiveness of this service.
- community pharmacy
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Pulmonary and Respiratory Medicine
Smith, S., Porteous, T., Bond, C., Francis, J., Lee, A. J., Lowrie, R., Scotland, G., Sheikh, A., Thomas, M., Wyke, S., & Smith, L. (2020). The Help for Hay Fever community pharmacy-based pilot randomised controlled trial for intermittent allergic rhinitis. npj Primary Care Respiratory Medicine, 30, 23. . https://doi.org/10.1038/s41533-020-0180-4